Kelly Hunt, MD
Surgical Oncology · Houston, TXNPI 1023114808
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $66,391 of the $103,909 with a category attached, or 63.9%. 9 manufacturers reported payments, led by Astrazeneca UK Limited at 38.2% of the total. 2025 is the largest year on record at $34,316, 3.8 times the $8,946 reported in 2019. Among surgical oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $1251.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$40K
- Merck$26K
- Daiichi Sankyo Inc.$19K
- AstraZeneca$18K
- Endomagnetics Ltd$210
- Leica Microsystems Inc.$190
- plus $350 from 3 others
Across 5 payments — averaging $20,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$103K
What the payments were for
- Consulting fees$66,39164%
- Speaking & faculty fees$12,88012%
- Travel & lodging$22,68222%
- Food & beverage$1,9442%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 17 | $39,712 |
| Merck | 42 | $26,394 |
| Daiichi Sankyo Inc. | 10 | $18,929 |
| AstraZeneca | 7 | $18,124 |
| Endomagnetics Ltd | 2 | $210 |
| Leica Microsystems Inc. | 1 | $190 |
| Gilead | 2 | $143 |
| Stemline Therapeutics Inc. | 1 | $128 |
| Dermavant Sciences, Inc. | 1 | $79 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$103,909 in reported general payments places this provider in the 95th percentile of 191 surgical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other surgical oncology in Houston
- Merrick RossHouston$216K
- Michael KimHouston$51K
- Jeffrey GershenwaldHouston$50K
- Naruhiko IkomaHouston$48K
- Anthony LucciHouston$41K
- Helmi KhadraHouston$39K
- Hop Tran CaoHouston$32K
- Rosario HwangHouston$25K
- Amanda ArringtonHouston$13K
- Jean-Nicolas VautheyHouston$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.